Table 3 (A) Cox Proportional Hazard ratios, 95% Confidence intervals (95%CI) and p-values for survival analysis of relapse free survival dichotomised based on presence or absence and of NUP98 IHC expression in the in-house TNBC TMA1 with matched gene expression. (B) Cox Proportional Hazard ratios, 95% Confidence intervals (95%CI) and p-values for univariate and multivariate survival analysis of relapse free and overall survival stratified based on absent (0), low (1) or high (2) NUP98 IHC expression in the in-house TNBC TMA1 with matched gene expression. Cox Proportional Hazard ratios, 95% Confidence intervals (95%CI) and p-values for univariate and multivariate survival analysis of (C) relapse free and (D) overall survival stratified based on absent (0), low (1) or high (2) NUP98 IHC expression in the in-house TNBC TMA2. (E) Cox Proportional Hazard ratios, 95% Confidence intervals (95%CI) and p-values for survival analysis of relapse free survival dichotomised based on presence or absence and of NUP96 IHC expression in the in-house TNBC TMA2
A | |||||
TNBC TMA #1 | N(n) | HR | %95 CI | p-value | |
Relapse Free Survival | 53(16) | Univariate | |||
Nup98 | absent | 15 (1) | 1 | ||
present | 37 (14) | 6.707 | 0.8815–51.04 | 0.066 | |
B | |||||
TNBC TMA #1 | N(n) | HR | %95 CI | p-value | |
Relapse Free Survival | 53(16) | Univariate | |||
Nup98 | low | 15 (1) | 1 | ||
medium | 19 (5) | 4.24 | 0.495–36.33 | 0.1871 | |
high | 18 (9) | 10.373 | 1.3035–82.54 | 0.0271* | |
Relapse Free Survival | Multivariate | ||||
Nup98 | low | 15 (1) | 1 | ||
medium | 19 (5) | 3.7522 | 0.41815–33.670 | 0.2375 | |
high | 18 (9) | 13.32 | 1.39448–127.242 | 0.0245* | |
Overall Survival | 53 (12) | Univariate | |||
Nup98 | low | 15 (1) | 1 | ||
medium | 19 (3) | 2.5638 | 0.266–24.65 | 0.415 | |
high | 18 (6) | 5.8375 | 0.7016–47.57 | 0.103 | |
C | |||||
TNBC TMA #2 | N(n) | HR | %95 CI | p-value | |
Relapse Free Survival | 63(24) | Univariate | |||
Nup98 | low | 10 (1) | 1 | ||
medium | 34 (14) | 5.044 | 0.6629–38.38 | 0.1181 | |
high | 19 (9) | 7.293 | 0.9324–57.04 | 0.0583 | |
Multivariate | |||||
Nup98 | low | 10 (1) | 1 | ||
medium | 34 (14) | 4.39 | 0.051–37.87 | 0.1783 | |
high | 19 (9) | 8.95 | 1.06–75.11 | 0.0433* | |
D | |||||
TNBC TMA #2 | N(n) | HR | %95 CI | p-value | |
Relapse Free Survival | 63(24) | Univariate | |||
Nup98 | low | 10 (1) | 1 | ||
medium | 34 (14) | 5.086 | 0.6685–38.70 | 0.1162 | |
high | 19 (9) | 6.558 | 0.8293–51.86 | 0.0747 | |
Multivariate | |||||
Nup98 | low | 10 (1) | 1 | ||
medium | 34 (14) | 4.71 | 0.552–40.11 | 0.1566 | |
high | 19 (9) | 7.91 | 0.94–66.62 | 0.0570 | |
E | |||||
TNBC TMA #2 | N(n) 53(16) | HR | %95 CI | p-value | |
Relapse Free Survival | |||||
Nup96 | absent | 53(21) | 1 | ||
present | 11(5) | 1.378 | 0.4839–4.234 | 0.5173 | |
Overall Survival | |||||
Nup96 | absent | 53 (20) | 1 | ||
present | 11 (5) | 1.418 | 0.4943–4.445 | 0.04825* | |